




About the Company

Onyx Pharmaceuticals is a biopharmaceutical company committed to developing therapeutics that improve the lives of individuals with cancer. Our lead product is Nexavar[®] (sorafenib) tablets, a novel, oral multiple kinase inhibitor that targets proteins involved in both tumor cell proliferation and angiogenesis (the formation of new blood vessels to support cancer cell growth). This product is being developed and marketed in collaboration with Bayer HealthCare Pharmaceuticals.

Nexavar is approved in more than 90 countries worldwide for the treatment of patients with hepatocellular carcinoma (HCC), or liver cancer, and in more than 95 countries for the treatment of patients with advanced renal cell carcinoma (RCC), or kidney cancer. Nexavar is the first approved oral targeted therapy for liver cancer and the only one shown to significantly improve overall survival in patients with the disease.

Nexavar is being investigated in several ongoing Phase 3 trials in non-small cell lung cancer, thyroid cancer and as an adjuvant treatment for liver and kidney. The agent is also being studied in multiple Phase 2 trials in breast cancer, colorectal cancer and ovarian cancer, as well as in several Phase 1b studies evaluating its use in combination with standard chemotherapies and other anticancer agents.



By exploiting the genetic differences between abnormal and healthy cells, Onyx is focused on providing a new generation of therapeutics to treat cancer.

Beyond Nexavar, Onyx is pursuing a proteasome inhibition development program. The proteasome has been validated as an important clinical target in cancer, and Onyx is developing next-generation proteasome inhibitors with a high degree of selectivity, with the goal of increasing therapeutic efficacy and reducing side effects.

The lead product candidate in this program is carfilzomib, a selective, next-generation compound that is currently in multiple clinical trials to evaluate its safety and efficacy for the treatment of patients with multiple myeloma and solid tumors. Among these studies, Onyx has initiated a Phase 3 study, known as the ASPIRE trial, evaluating carfilzomib in combination with lenalidomide and low-dose dexamethasone for patients with relapsed multiple myeloma. As well, enrollment has been completed in a Phase 2b monotherapy trial, known as the 003-A1 trial, evaluating carfilzomib in patients with relapsed and refractory multiple myeloma, the pivotal trial that could support a new drug application (NDA) filing by the end of 2010. Top-line results are expected mid-2010.

In addition to carfilzomib, the proteasome inhibitor development program includes ONX 0912 (formerly PR-047), an oral proteasome inhibitor currently in Phase 1 testing in advanced solid tumors, and ONX 0914 (formerly PR-957), an immunoproteasome inhibitor with activity in preclinical models of autoimmune disorders.

Onyx has also established a development pipeline of anticancer compounds at various stages of clinical testing. Onyx is developing ONX 0801, a targeted alpha-folate inhibitor that recently entered into Phase 1 testing. Onyx also has options to license the rights to two Janus Kinase 2 (JAK2) inhibitors: ONX 0803, in Phase 1 studies to treat primary myelofibrosis and lymphoid malignancies, and ONX 0805, currently in preclinical development. PD 0332991, an oral, small molecule cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, now in Phase 2 clinical development, resulted from a collaboration with Warner-Lambert Company, now Pfizer. Pfizer is responsible for all product development activities and costs. In exchange, Onyx will receive milestone payments and a single-digit royalty on any worldwide sales of the product.

Onyx common stock is traded on the Nasdaq Global Market under the symbol ONXX.